Abbvie’s RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis May 4, 2022 | BioForward Member News Read the full Abbvie press release here
Sep 28 2023 BioForward Advocacy Achieves Results: Understanding the Impact of Recent State and Federal Legislation on Biohealth Companies
Oct 25 2023 Introduction of a New Thiol-based Fluorescent Indicator to Assess Cellular Health Using Induced Pluripotent Stem Cell Derived Neurons